Clinical Progress and Business Updates in Oncology Pipeline Reported by Nimbus Therapeutics Nimbus Therapeutics, a biotechnology company leveraging its advanced computational drug discovery engine to develop breakthrough medicines, today announced significant progress in its clinical oncology pipeline. Additionally, the company…
Reports Complete Response in First Infant with ECUR-506 for OTC Deficiency, iECURE iECURE, Inc., a gene-editing company focused on developing in vivo gene insertion therapies for liver disorders, reports promising preliminary findings from the first infant dosed in the ongoing…
Colorectal Cancer: SOTIO Advances SOT109 ADC and Licenses Antibodies from Biocytogen SOTIO Biotech, a clinical-stage biopharmaceutical company owned by the PPF Group, has announced an exciting milestone in the development of its novel antibody-drug conjugate (ADC) candidate, SOT109. The company…
Pharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial Thetis Pharmaceuticals LLC, a clinical-stage company focused on developing TP-317, a pioneering small molecule drug targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis, has…
Appoints Eric Davidson as Chief Commercial Officer Mendaera Inc., a healthcare technology company focused on developing an innovative handheld robotic platform for interventional procedures, appoints Eric Davidson as its first Chief Commercial Officer (CCO). In this newly created role, Davidson…
Cyrus Selects CYR212 as Candidate for IgG-Driven Autoimmune Diseases Cyrus Biotechnology, an AI-driven therapeutics company, announced the selection of CYR212 as its clinical development candidate for chronic IgG-driven autoimmune diseases. CYR212 is a next-generation, engineered Immunoglobulin-G (IgG) protease designed to…
Peanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers Stallergenes Greer, a biopharmaceutical company specializing in allergen immunotherapy (AIT), has announced that the European Commission (EC) has granted approval for the extension of Palforzia® (defatted powder of Arachis…
Cardiometabolic Innovator Verdiva Bio Launches with $410M+ Series A to Advance Therapies Verdiva Bio Limited (“Verdiva”), a new clinical-stage biopharmaceutical company, announced its official launch today, aiming to innovate therapies for obesity and other cardiometabolic disorders. The company has raised…
Ambry Genetics Data Enhances BRCA2 Variant Classification for Hereditary Cancers Ambry Genetics, a leader in clinical genomic testing, has announced its contribution to a groundbreaking study published in Nature, which significantly enhances the understanding of BRCA2 gene variants. As genetic…
MaaT Pharma Announces Positive Phase 3 ARES Results for MaaT013 in Acute GvHD MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company specializing in Microbiome Ecosystem Therapies™ (MET) to improve survival for cancer patients through immune modulation, has announced positive topline…
Cofactor Genomics Announces CEO Change for Growth and OncoPrism Expansion Cofactor Genomics, Inc., a leader in precision medicine through RNA decoding, has appointed Chris Parker as CEO and Board Member to drive the company’s efforts in advancing immunotherapy. At the…
VitVio Enhances Orthopaedic Hospital OR Efficiency and Safety with AI Platform The Royal Orthopaedic Hospital (ROH), one of the UK’s leading institutions in orthopaedic care, has launched a pilot program with VitVio, a company at the forefront of integrating artificial…